Ionis Pharma (IONS) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Reports Financial Results and Highlights for First Quarter 2016
May 4, 2016 7:30 AM EDTCARLSBAD, Calif., May 4, 2016 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter were in line with the company's expectations.
"2016 is off to a strong start. Target enrollment is complete in four Phase 3 studies across nusinersen, IONIS-TTRRx and volanesorsen. These important new drugs are now one step closer to... More
